Chemical Property of Lixisenatide
Edit
Chemical Property:
- PSA:2085.46000
- LogP:2.13170
- Purity/Quality:
-
Lixisenatide >98% *data from reagent suppliers
Safty Information:
- Pictogram(s):
- Hazard Codes:
- MSDS Files:
-
SDS file from LookChem
Useful:
-
Description
Lixisenatide injection is used to treat type 2 diabetes mellitus. Lixisenatide is used together with diet and exercise to help control your blood sugar. This medicine is a glucagon-like peptide-1 (GLP-1) receptor agonist.
-
Uses
Lixisenatide injection is used along with diet and exercise to treat type 2 diabetes (condition in which the body does not use insulin normally and therefore cannot control the amount of sugar in the blood). Lixisenatide injection is not used to treat type 1 diabetes (condition in which the body does not produce insulin and therefore cannot control the amount of sugar in the blood). Lixisenatide is not used instead of insulin to treat people with diabetes who need insulin. Lixisenatide injection is in a class of medications called incretin mimetics. It works by stimulating the pancreas to secrete insulin when blood sugar levels are high. Insulin helps move sugar from the blood into other body tissues where it is used for energy. Lixisenatide injection also slows the emptying of the stomach and causes a decrease in appetite.
-
Indications
Both Adlyxin and Soliqua 100/33 are FDA-approved as adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Soliqua 100/33 is indicated specifically in those inadequately controlled on basal insulin (less than 60 units daily) or lixisenatide.
-
Clinical Use
#N/A
-
Drug interactions
Potentially hazardous interactions with other drugs
Anti-arrhythmics: concentration of lomitapide
possibly increased by dronedarone - avoid.
Antibacterials: concentration of lomitapide possible
increased by clarithromycin and erythromycin -
avoid.
Anticoagulants: increases warfarin concentration.
Antifungals: concentration of lomitapide possibly
increased by ketoconazole and triazoles - avoid.
Antivirals: concentration of lomitapide possibly
increased by darunavir, fosamprenavir, indinavir,
lopinavir, ritonavir, saquinavir, telaprevir and
tipranavir - avoid.
Bicalutamide: separate lomitapide and bicalutamide
administration by 12 hours.
Calcium channel blockers: concentration of
lomitapide possibly increased by diltiazem and
verapamil - avoid.
Lipid lowering agents: reduce simvastatin dose by
50% if used together